Toxicology and adverse effects of drugs used for immunosuppression in organ transplantation

Clinics in Laboratory Medicine

Volumn 18, Issue 4, 1998, Pages 755-765

  Philip, A T ^a   Gerson, B ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; BREQUINAR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LEFLUNOMIDE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ALOPECIA; BONE MARROW DEPRESSION; CUSHING DISEASE; DRUG EFFECT; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; GROWTH RETARDATION; HUMAN; HYPERTENSION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA;

EID: 0031797270     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0272-2712(18)30150-1     Document Type: Review

References (22)

1. Abraham R.T. Wiederrecht G.J. Immunopharmacology of rapamycin Annu Rev Immunol 14 1996 483 510
2. Allison A.C. Eugui E.M. Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs Transplant Proc 25 suppl 2 1993 8 18
3. Allison A.C. Kowalski W.Y. Muller C.J. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis block the glycosylation of adhesion molecules Transplant Proc 25 suppl 2 1993 67 70
4. Barry J.M. Immunosuppressive drugs in renal transplantation Drugs 44 1992 554 556
5. Bonnefoy-Berard N. Revillard J-P. Mechanism of immunosuppression induced by antithymocyte globulins and OKT3 J Heart Lung Transplant 15 1996 435 442
6. Brazelton T.R. Morris R.E. Molecular mechanism of action of xenobiotic immunosuppressive drugs: Tacrolimus (FK 506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide Curr Opin Immunol 8 1996 710 720
7. Constanzo M.R. Immunosuppression in organ transplantation Kolbeck K.C. Markin R.S. McManus B.M. Transplant Pathology 1994 ASCP Press Chicago 45 61
8. Flye M.W. History of transplantation Flye M.W. Principles of Organ Transplantation 1989 WB Saunders Philadelphia 1 17
9. Flye M.W. Immunosuppressive therapy Flye M.W. Principles of Organ Transplantation 1989 WB Saunders Philadelphia 155 175
10. Graham R.M. Cyclosporine: Mechanism of action and toxicity Cleve Clin J Med 61 1994 308 313
11. Groth C.G. Obiman S. Gannedahl G. Ericzon B-G. New immunosuppressive drugs in transplantation Transplant Proc 25 1993 2681 2683
12. Haydon G.H. Hayes P.C. New immunosuppressive treatment in transplantation medicine Ballieres Clinical Gastroenterol 8 1994 455 464
13. Kolbeck P.C. Johnson D.R. Klassen L.W. Sharp J.G. The pathophysiology of rejection Kolbeck K.C. Markin R.S. McManus B.M. Transplant Pathology 1994 ASCP Press Chicago 1 18
14. Makowka L. Chapman F. Cramer D.V. Historical development of brequinar sodium as a new immunosuppressive drug for transplantation Transplant Proc 25 suppl 2 1993 2 7
15. Morris R.E. New small molecule immunosuppressants for transplantation: Review of essential concepts J Heart Lung Transplant 12 1993 S275 286
16. Morris R.E. Mechanism of action of new immunosuppressive drugs Ther Drug Monit 17 1995 564 569
17. Olshan A.F. Mattison D.R. Zwanenburg T.S.B. Cyclosporine A: Review of genotoxicity and potential for adverse human reproductive and developmental effects Mutat Res 317 1994 163 173
18. Renlund D.G. Gopinathan S.K. Kfoury A.G. Taylor D.O. Mycophenolate mofetil (MMF) in heart transplantation: Rejection prevention and treatment Clin Transplant 10 1996 136 139
19. Sollinger H.W. From mice to man: The preclinical history of mycophenolate mofetil Clin Transplant 10 1996 85 92
20. Suthanthiran M. Strom T.B. Immunobiology and immunopharmacology of organ allograft rejection J Clin Immunol 15 1995 161 171
21. Taesch S. Niese D. Mueller E.A. Sandimmun Neoral, a new oral formulation of eye A with improved pharmacokinetic characteristics: Safety and tolerability in renal transplant patients Transplant Proceed 26 1994 3147 3149
22. Whiting P.H. Acute and chronic nephrotoxicity associated with immunosuppressive drugs Curr Opin Nephrol Hypertens 3 1994 174 181